N-acetylcysteine Protects Against Myocardial Ischemia-Reperfusion Injury Through Anti-ferroptosis in Type 1 Diabetic...

Area of Science:

• Cardiovascular Science
• Metabolic Disease Research
• Cellular Injury Mechanisms

Background:

• Diabetes mellitus significantly increases the risk of myocardial ischemia-reperfusion injury (IRI).
• Early diabetes may paradoxically confer resistance to IRI, with mechanisms remaining unclear.
• Ferroptosis, a regulated cell death pathway, is implicated in myocardial IRI, particularly in diabetic conditions.

Purpose of the Study:

• To investigate the role of ferroptosis in the changing vulnerability of diabetic hearts to IRI over time.
• To determine the protective mechanisms of N-acetylcysteine (NAC) against myocardial IRI in diabetes.

Main Methods:

• Streptozotocin-induced diabetic (DM) and non-diabetic control (NC) mice were subjected to myocardial IRI.
• Mice received N-acetylcysteine (NAC) treatment starting one week after diabetes induction.
• Myocardial infarct size, ferroptosis markers, and oxidative stress were assessed at 1, 2, and 5 weeks post-diabetes induction.

Main Results:

• Diabetic mice showed reduced infarct size at 1 week but increased infarct size at 2 and 5 weeks compared to NC mice.
• Ferroptosis was reduced at 1 week and increased at 2 and 5 weeks in diabetic hearts.
• NAC treatment attenuated ferroptosis, oxidative stress, and reduced infarct size in diabetic mice at later time points.

Conclusions:

• Increased oxidative stress and ferroptosis contribute to heightened myocardial IRI vulnerability in later stages of diabetes.
• N-acetylcysteine (NAC) confers cardioprotection against diabetic myocardial IRI by attenuating ferroptosis.
• Targeting ferroptosis presents a potential therapeutic strategy for managing myocardial IRI in diabetic patients.